Skip to Content
Merck

SFRVN

Sf-RVN® Insect Cell Line

Synonym(s):

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

Sign In to View Organizational & Contract Pricing

Select a Size

SFRVN-RA-IF

23 040,00 kr

SFRVN-RA-AF

57 600,00 kr

SFRVN-C1-AF

746 530,00 kr

SFRVN-C1-IF

746 530,00 kr

SFRVN-C2

8 607 060,00 kr

SFRVN-C3

37 875 450,00 kr

23 040,00 kr


Please contact Customer Service for Availability


About This Item

UNSPSC Code:
41116105

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Sf9 rhabdovirus-negative (Sf-RVN®) Insect Cell Line

solubility

DMSO: 10%

shipped in

liquid nitrogen

storage temp.

−196°C

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
14380C24381CPTMP24H48
storage temp.

−196°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

-

shipped in

liquid nitrogen

shipped in

ambient

shipped in

ambient

shipped in

-

description

Sf9 rhabdovirus-negative (Sf-RVN) Insect Cell Line

description

-

description

-

description

-

solubility

DMSO: 10%

solubility

-

solubility

-

solubility

-

General description

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106 cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO.
The Sf-RVN® Insect Cell Line is a rhabdovirus-negative Sf9 cell line that can be grown in both adherent and suspension culture. Sf-RVN® Insect Cell Line has been adapted for growth in chemically defined medium to be used for the production of recombinant proteins, adeno-associated viruses (AAV) and viral-like particles (VLP). The cell line was tested for adventitious agents and banked under GMP conditions. A technical user guide, with detailed protocols for optimal performances, is provided with the cell line.The EX-CELL® CD Insect Cell Medium, recommended for use, is optimized to get excellent growth and productivity of the Sf-RVN® Insect Cell Line. Combined, these two products form the Sf-RVN® Platform.

Cell Line Origin

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Physical form

Sf-RVN® cells are provided to customers in vials containing 1 mL at 10 x 106cells/mL. Cells are banked in EX-CELL® CD Insect Cell Medium and 10% DMSO

Other Notes

Sf-RVN® is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN® was isolated from Sf9 by GlycoBac, LLC.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany
Sf-RVN is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.

Upstream gene therapy optimization maximizes viral vector titers; partner with technology experts for HEK293, HEK293T, and Sf9 cell solutions.

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

See All

Related Content

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service